Petros Grivas

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus

  ESMO Open · 2026-06-12

• Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists

  Clinical Genitourinary Cancer · 2025-12-20

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  UNC Libraries · 2025-12-19

• Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

  CA A Cancer Journal for Clinicians · 2025-12-13

• supplementary table TS1 from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

  2025-11-25

• A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

  Future Oncology · 2025-11-23 · 1 citations

• Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study

  ESMO Open · 2025-11-20 · 1 citations

• 864 Delineating the role of growth differentiation Factor 15 (GDF-15) in advanced bladder and upper tract urinary cancers (BC): university of Washington rapid autopsy program (UW-RAP) cohort

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

  Urologic Oncology Seminars and Original Investigations · 2025-10-28

• Efficacy of erdafitinib before or after enfortumab vedotin in <i>FGFR3</i> -altered advanced urothelial cancer: analysis of the UNITE collaborative study

  The Oncologist · 2025-10-05

• Impact of research nurse clinical trial pre-screening on enrollment of underrepresented populations in genitourinary oncology (GU Onc) clinical trials at a large academic center.

  JCO Oncology Practice · 2025-10-01

• Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the <scp>UNITE</scp> Study

  Cancer Medicine · 2025-10-01 · 4 citations

• End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

  Journal of Clinical Oncology · 2025-09-11 · 14 citations

• Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis

  iGIE · 2025-09-05 · 1 citations

• Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study

  Urologic Oncology Seminars and Original Investigations · 2025-09-02 · 2 citations

• A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy

  Future Oncology · 2025-09-01

• 3094P Validation of prognostic scores for advanced urothelial cancer (aUC) for enfortumab vedotin/pembrolizumab (EVP): Analysis of the UNITE study

  Annals of Oncology · 2025-09-01

• 3083P JAVELIN bladder medley phase II trial of avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Subgroup analyses based on metastatic sites

  Annals of Oncology · 2025-09-01

• Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

  European Urology · 2025-09-01 · 10 citations

• 3135eTiP INTerpath-011: Phase II study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC)

  Annals of Oncology · 2025-09-01 · 1 citations